Who May Be at Risk for Gastroparesis While Taking Ozempic?
Latest update (2026-01)
- FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]
From General Health Information to Targeted Pharmacovigilance
If you're experiencing persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be concerned about gastroparesis—a condition where the stomach empties too slowly. Decades of pharmacovigilance have established that certain medications can affect gastrointestinal motility, and recent reports have raised questions about GLP-1 receptor agonists like Ozempic. This page reviews the FDA's warning and the clinical evidence to help you understand the potential risks.
Understanding Ozempic and Its Mechanism of Action
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its mechanism of action includes slowing gastric emptying, which contributes to its glucose-lowering effects but also raises concerns about gastrointestinal adverse events, including gastroparesis. Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy or breath tests, and management focuses on dietary modifications, prokinetic agents, and antiemetics. The prescribing information for Ozempic documents a significantly higher incidence of gastrointestinal adverse reactions compared to placebo. In pooled placebo-controlled trials, gastrointestinal adverse reactions occurred in 32.7% of patients receiving Ozempic 0.5 mg and 36.4% of those receiving Ozempic 1 mg, versus 15.3% in the placebo group (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and diarrhea occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher in Ozempic-treated patients: 3.1% for the 0.5 mg dose and 3.8% for the 1 mg dose, compared to 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred in 30.8% and 34.0% of patients, respectively (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
Clinical Evidence Linking Ozempic to Gastroparesis Symptoms
Specific adverse reactions reported in at least 5% of Ozempic-treated patients include nausea (15.8% for 0.5 mg, 20.3% for 1 mg), vomiting (5.0% for 0.5 mg, 9.2% for 1 mg), diarrhea (8.5% for 0.5 mg, 8.8% for 1 mg), abdominal pain (7.3% for 0.5 mg, 5.7% for 1 mg), and constipation (5.0% for 0.5 mg, 3.1% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with the clinical presentation of gastroparesis, though the prescribing information does not explicitly list gastroparesis as a separate adverse reaction. The label does, however, list pancreatitis, diabetic retinopathy complications, hypoglycemia, acute kidney injury, hypersensitivity, and acute gallbladder disease as serious adverse reactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Mechanistically, GLP-1 receptor agonists like Ozempic delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This pharmacodynamic effect is dose-dependent and can become pathological in susceptible individuals, leading to gastroparesis. The timeline between exposure and documented harm is variable; gastrointestinal symptoms often emerge during dose escalation, as noted in clinical trials, but persistent or severe cases may develop after weeks to months of treatment.
Risk Assessment and Causation Considerations
The adequacy of warnings regarding Ozempic and gastroparesis is a subject of ongoing discussion. While the label highlights common gastrointestinal adverse reactions, it does not specifically warn of gastroparesis as a distinct condition. This gap may affect patient awareness and early recognition of symptoms that could indicate delayed gastric emptying. For affected patients, causation considerations involve evaluating the temporal relationship between Ozempic initiation and symptom onset, ruling out other causes of gastroparesis (e.g., diabetes-related autonomic neuropathy, prior surgery, or idiopathic factors), and assessing the dose-response relationship. The high incidence of gastrointestinal adverse reactions in clinical trials supports a plausible causal link, but individual susceptibility varies. Patients experiencing persistent nausea, vomiting, or abdominal pain should be evaluated for gastroparesis, and discontinuation of Ozempic may lead to symptom improvement. The risk of harm is underscored by the potential for severe complications, including malnutrition, electrolyte imbalances, and aspiration pneumonia. In summary, the evidence from clinical trials demonstrates a clear association between Ozempic use and gastrointestinal adverse reactions that mimic gastroparesis. The prescribing information provides data on the frequency of these reactions but does not explicitly address gastroparesis as a warning. Clinicians and patients should remain vigilant for symptoms of delayed gastric emptying, particularly during dose escalation, and consider alternative therapies if such symptoms arise. Further research is needed to clarify the incidence of confirmed gastroparesis in Ozempic users and to optimize risk communication. References: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the FDA warning about Ozempic and gastroparesis?
The FDA has highlighted a potential signal linking Ozempic (semaglutide) to an increased risk of gastroparesis, a condition of delayed gastric emptying. While the prescribing information lists common gastrointestinal adverse reactions like nausea and vomiting, it does not explicitly warn of gastroparesis as a distinct condition. Patients and clinicians are advised to monitor for symptoms of delayed gastric emptying, especially during dose escalation.
How common are gastrointestinal side effects with Ozempic?
In clinical trials, gastrointestinal adverse reactions occurred in 32.7% of patients receiving Ozempic 0.5 mg and 36.4% of those receiving 1 mg, compared to 15.3% with placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific reactions include nausea (up to 20.3%), vomiting (up to 9.2%), diarrhea (up to 8.8%), abdominal pain (up to 7.3%), and constipation (up to 5.0%).
What should I do if I experience symptoms of gastroparesis while taking Ozempic?
If you experience persistent nausea, vomiting, early satiety, bloating, or abdominal pain while taking Ozempic, consult your healthcare provider. They may evaluate you for gastroparesis using tests like gastric emptying scintigraphy. Discontinuation of Ozempic may lead to symptom improvement. Do not stop medication without medical advice.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
- Statute of limitations for Ozempic in New York
- Statute of limitations for Ozempic in Virginia
- Statute of limitations for Ozempic in Texas
- Is Gastroparesis from Ozempic permanent
- Treatment for severe Gastroparesis after Ozempic
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.